ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
CANbridge signs license agreement with Mirum for maralixibat in Greater China
May 07, 2021Biopharmaceutical company CANbridge Pharmaceuticals has signed a licensing agreement with Mirum Pharmaceuticals for the development and commercialisation of maralixibat in Greater China. -
Mirum Initiates Maralixibat Phase 3 Clinical Trial
July 10, 2019Mirum Pharmaceuticals announced the dosing of the first patient in the Phase 3 MARCH-PFIC clinical trial of its lead drug candidate, maralixibat, in pediatric patients with progressive familial intrahepatic cholestasis (PFIC).
Pharma Sources Insight January 2025
